SG-3-06686 overview
SG-3-06686 binds to CXCR3 receptor on dendritic cells, amplifies the natural ligand which induces a robust immune cell migration to the tumor microenvironment, ultimately resulting in tumor shrinkage.
Microbiome comparison between anti-PD-1 nonresponders and responders
Anti-PD-1
non-responders
Anti-PD-1
responders
Identify peptide
enriched in anti-PD-1
responders
Engineered
SG-3-6686
peptide
SG-3-6686 peptide binds to CXCR3 receptor on dendritic cells
Amplifies natural ligand inducing robust immune cell migration to tumor microenvironment
Tumor shrinkage with single agent and in combination with anti-PD-1 in vivo
Tumor shrinkage in non-responders
SG-3-06686 targets recruitment of immune cells
Publications
External data and Second Genome internal data demonstrate CXCR3 chemokine system plays a key role in cancer
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond
Nathan Karin
Frontiers in Immunology.
1 May 2020. Volume 11.
Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy
Melvyn T. Chow et al.
Immunity 50, 1498–1512 June 18, 2019
The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer.
Tino Vollmer et al.
Sci. Transl. Med. 13, 13 January 2021